Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurence Corash

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Transfusion|January 10, 2006
Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A lightScott Murphy, Edward Snyder, Ritchard Cable, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|November 20, 2019
Amotosalen-inactivated fresh frozen plasma is comparable to solvent-detergent inactivated plasma to treat thrombotic thrombocytopenic purpuraOlivier Garraud, Sandrine Malot, Raoul Herbrecht, et al.
Transfusion|March 19, 2008
A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatmentJean C Osselaer, Nathalie Messe, Tor Hervig, et al.
Transfusion|September 21, 2010
Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year periodJean-Pierre Cazenave, Hervé Isola, Chantal Waller, et al.
Transfusion|January 13, 2025
Human leukocyte antigen alloimmunization in a randomized trial of amustaline/glutathione pathogen-reduced red cells in complex cardiac surgery patientsPhilip J Norris, Mars Stone, Clara Di Germanio, et al.
Blood|January 18, 2006
Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver diseasePaul D Mintz, Nathan M Bass, Lawrence D Petz, et al.
Transfusion|December 9, 2004
Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A lightEdward Snyder, Thomas Raife, Lily Lin, et al.
Transfusion|April 25, 2009
Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component useJean Claude Osselaer, Chantal Doyen, Laurence Defoin, et al.
British Journal of Haematology|June 1, 2019
Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemiaYesim Aydinok, Antonio Piga, Raffaella Origa, et al.
Transfusion|March 25, 2009
Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La RéunionPatrice Rasonglès, Marie France Angelini-Tibert, Philip Simon, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Transfusion|January 10, 2006
Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A lightScott Murphy, Edward Snyder, Ritchard Cable, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|November 20, 2019
Amotosalen-inactivated fresh frozen plasma is comparable to solvent-detergent inactivated plasma to treat thrombotic thrombocytopenic purpuraOlivier Garraud, Sandrine Malot, Raoul Herbrecht, et al.
Transfusion|March 19, 2008
A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatmentJean C Osselaer, Nathalie Messe, Tor Hervig, et al.
Transfusion|September 21, 2010
Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year periodJean-Pierre Cazenave, Hervé Isola, Chantal Waller, et al.
Transfusion|January 13, 2025
Human leukocyte antigen alloimmunization in a randomized trial of amustaline/glutathione pathogen-reduced red cells in complex cardiac surgery patientsPhilip J Norris, Mars Stone, Clara Di Germanio, et al.
Blood|January 18, 2006
Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver diseasePaul D Mintz, Nathan M Bass, Lawrence D Petz, et al.
Transfusion|December 9, 2004
Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A lightEdward Snyder, Thomas Raife, Lily Lin, et al.
Transfusion|April 25, 2009
Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component useJean Claude Osselaer, Chantal Doyen, Laurence Defoin, et al.
British Journal of Haematology|June 1, 2019
Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemiaYesim Aydinok, Antonio Piga, Raffaella Origa, et al.
Transfusion|March 25, 2009
Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La RéunionPatrice Rasonglès, Marie France Angelini-Tibert, Philip Simon, et al.
Pageof 7